Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects
Paweł Zajdel, Tomasz Kos, Krzysztof Marciniec, et al.
European Journal of Medicinal Chemistry (2018) Vol. 145, pp. 790-804
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Sulfonamide derivatives as multi-target agents for complex diseases
Sinem Apaydın, Marianna Török
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 16, pp. 2042-2050
Closed Access | Times Cited: 200
First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease
Patryk Pyka, Wawrzyniec Haberek, Małgorzata Więcek, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1580-1610
Open Access | Times Cited: 12
Effects of ketamine on rat social behavior as analyzed by DeepLabCut and SimBA deep learning algorithms
Piotr Popik, Ewelina Cyrano, Diana Piotrowska, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 9
Multi-Target Approach for Drug Discovery against Schizophrenia
Magda Kondej, Piotr Stępnicki, Agnieszka A. Kaczor
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3105-3105
Open Access | Times Cited: 80
The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment
Gniewomir Latacz, Annamaria Lubelska, Magdalena Jastrzębska‐Więsek, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 14, pp. 3420-3420
Open Access | Times Cited: 50
Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics
Samantha Álvarez-Herrera, Raúl Escamilla, Óscar Medina‐Contreras, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 37
Computational approaches for the design of novel dopamine D2 and serotonin 5-HT2A receptor dual antagonist towards schizophrenia
Akash Rathore, Vivek Asati, Mitali Mishra, et al.
In Silico Pharmacology (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Multistep Mechanochemical Synthesis of PZ-1190, a Multitarget Antipsychotic Agent
Vittorio Canale, Michał Kamiński, Wojciech Trybała, et al.
ACS Sustainable Chemistry & Engineering (2023) Vol. 11, Iss. 45, pp. 16156-16164
Open Access | Times Cited: 12
Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease
Kinga Czarnota-Łydka, Sylwia Sudoł-Tałaj, Katarzyna Kucwaj‐Brysz, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115695-115695
Open Access | Times Cited: 10
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
Anna Partyka, Joanna Gołębiowska, Krzysztof Marciniec, et al.
Pharmacological Reports (2025)
Closed Access
5-HT1A receptor ligands and their therapeutic applications: review of new patents
Jakub Staroń, Ryszard Bugno, Adam S. Hogendorf, et al.
Expert Opinion on Therapeutic Patents (2018) Vol. 28, Iss. 9, pp. 679-689
Closed Access | Times Cited: 29
Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro
Annamaria Lubelska, Gniewomir Latacz, Magdalena Jastrzębska‐Więsek, et al.
Molecules (2019) Vol. 24, Iss. 24, pp. 4472-4472
Open Access | Times Cited: 23
Sustainable Synthesis of a Potent and Selective 5-HT7 Receptor Antagonist Using a Mechanochemical Approach
Vittorio Canale, Valeria Frisi, Xavier Bantreil, et al.
The Journal of Organic Chemistry (2020) Vol. 85, Iss. 16, pp. 10958-10965
Open Access | Times Cited: 22
A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties
Vittorio Canale, Katarzyna Grychowska, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112765-112765
Open Access | Times Cited: 22
Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States
David Vanda, Vittorio Canale, Séverine Chaumont‐Dubel, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 2, pp. 1180-1196
Closed Access | Times Cited: 20
Design and Screening of New Lead Compounds for Autism Based on QSAR Model and Molecular Docking Studies
Yongjian Chen, Kang Ma, Peilong Xu, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7285-7285
Open Access | Times Cited: 13
Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo
Sylwia Sudoł, Katarzyna Kucwaj‐Brysz, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112529-112529
Open Access | Times Cited: 19
Multi-targeted drug design strategies for the treatment of schizophrenia
Piotr Stępnicki, Magda Kondej, Oliwia Koszła, et al.
Expert Opinion on Drug Discovery (2020) Vol. 16, Iss. 1, pp. 101-114
Closed Access | Times Cited: 19
Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties
Paweł Zajdel, Katarzyna Grychowska, Szczepan Mogilski, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13279-13298
Open Access | Times Cited: 17
1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT6R Antagonists: Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity
Vittorio Canale, Wojciech Trybała, Séverine Chaumont‐Dubel, et al.
Biomolecules (2022) Vol. 13, Iss. 1, pp. 12-12
Open Access | Times Cited: 12
Current development in sulfonamide derivatives to enable CNS-drug discovery
Klaudia Blicharz-Futera, Michał Kamiński, Katarzyna Grychowska, et al.
Bioorganic Chemistry (2024) Vol. 156, pp. 108076-108076
Closed Access | Times Cited: 2
Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands
Grzegorz Ślifirski, Marek Król, Jerzy Kleps, et al.
European Journal of Medicinal Chemistry (2019) Vol. 166, pp. 144-158
Closed Access | Times Cited: 18
The Recent Development of Piperazine and Piperidine Derivatives as Antipsychotic Agents
Akash Rathore, Vivek Asati, Sushil K. Kashaw, et al.
Mini-Reviews in Medicinal Chemistry (2020) Vol. 21, Iss. 3, pp. 362-379
Closed Access | Times Cited: 17
Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder
Enza Lacivita, Mauro Niso, Margherita Mastromarino, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 8, pp. 1313-1327
Open Access | Times Cited: 16
An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential
Katarzyna Kucwaj‐Brysz, Wesam Ali, Rafał Kurczab, et al.
Bioorganic Chemistry (2022) Vol. 121, pp. 105695-105695
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top